Format

Send to

Choose Destination
Oncoimmunology. 2014 Mar 27;3:e28273. eCollection 2014.

Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis.

Author information

1
OREGA Biotech; Ecully, France.
2
IRCM, Institut de Recherche en Cancérologie de Montpellier; INSERM, U896; Université Montpellier 1; CRLC Val d'Aurelle Paul Lamarque; Montpellier, France.
3
IRCM, Institut de Recherche en Cancérologie de Montpellier; INSERM, U896; Université Montpellier 1; CRLC Val d'Aurelle Paul Lamarque; Montpellier, France ; Département d'Immunologie; Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine Université Montpellier 1; Montpellier, France.
4
Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976; Paris, France ; Université Paris Diderot; Sorbonne Paris Cité; Laboratoire Immunologie Dermatologie & Oncologie; Paris, France.

Abstract

We have previously reported that a subset of breast tumors are infiltrated with IL-17A-producing tumor-associated lymphocytes and that IL-17A cytokine is principally associated with estrogen receptor negative (ER-) and triple negative, basal-like tumors. We established that IL-17A producing lymphocytes induced cancer cell proliferation, chemoresistance, and invasion, indicating that IL-17A is a potential therapeutic target for breast malignancies.

KEYWORDS:

ERK kinases; IL-17A; breast cancer; chemoresistance; monoclonal antibodies; tumor infiltrating lymphocytes

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center